227 related articles for article (PubMed ID: 23470823)
1. [Management of late complications after allogeneic hematopoietic stem cell transplantation].
Kurosawa S; Fukuda T
Rinsho Ketsueki; 2013 Feb; 54(2):167-76. PubMed ID: 23470823
[No Abstract] [Full Text] [Related]
2. Prognostic factors identifiable at the time of onset of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.
Remberger M
Haematologica; 2005 Jul; 90(7):870. PubMed ID: 15996922
[No Abstract] [Full Text] [Related]
3. Clinical features of late onset non-infectious pulmonary complications following pediatric allogeneic hematopoietic stem cell transplantation.
Park M; Koh KN; Kim BE; Im HJ; Seo JJ
Clin Transplant; 2011; 25(2):E168-76. PubMed ID: 21077955
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic PBPC transplantation: an effect on incidence and distribution of chronic graft-versus-host disease without long-term survival benefit?
Snowden JA; Nivison-Smith I; Atkinson K; Fay K; Concannon A; Dodds A; Milliken S; Biggs J
Bone Marrow Transplant; 2000 Jan; 25(1):119-20. PubMed ID: 10654027
[No Abstract] [Full Text] [Related]
5. [Complications of hematopoietic stem cell transplantation: physiopathology and management. 2. Graft-versus-host disease (GVHD)].
Morishita Y
Nihon Naika Gakkai Zasshi; 1998 Aug; 87(8):1502-9. PubMed ID: 9780678
[No Abstract] [Full Text] [Related]
6. Bandage and scleral contact lenses for ocular graft-versus-host disease after allogeneic haematopoietic stem cell transplantation.
Stoyanova EI; Otten HM; Wisse R; Rothova A; Riemens A
Acta Ophthalmol; 2015 Nov; 93(7):e604. PubMed ID: 25923173
[No Abstract] [Full Text] [Related]
7. Ex vivo selection of recipient-type alloantigen-specific CD4(+)CD25(+) immunoregulatory T cells for the control of graft-versus-host disease after allogeneic hematopoietic stem-cell transplantation.
Trenado A; Fisson S; Braunberger E; Klatzmann D; Salomon BL; Cohen JL
Transplantation; 2004 Jan; 77(1 Suppl):S32-4. PubMed ID: 14726768
[TBL] [Abstract][Full Text] [Related]
8. Biology and management of chronic graft-versus-host disease.
Martin PJ; Pavletic SZ
Cancer Treat Res; 2009; 144():277-98. PubMed ID: 19779885
[No Abstract] [Full Text] [Related]
9. [Pay attention to diagnosis and treatment of complications after hematopoietic stem cell transplantation].
Huang XJ
Zhonghua Xue Ye Xue Za Zhi; 2008 Aug; 29(8):505-6. PubMed ID: 19112910
[No Abstract] [Full Text] [Related]
10. Challenges to preventing infectious complications, decreasing re-hospitalizations, and reducing cost burden in long-term survivors after allogeneic hematopoietic stem cell transplantation.
Fuji S; Kapp M; Einsele H
Semin Hematol; 2012 Jan; 49(1):10-4. PubMed ID: 22221780
[TBL] [Abstract][Full Text] [Related]
11. Jaundice after allogeneic hematopoietic stem cell transplantation.
Mendizabal M; Chen T; Reddy KR
Hepatology; 2009 Dec; 50(6):2044-5. PubMed ID: 19937681
[No Abstract] [Full Text] [Related]
12. [Induction of aGVHD after allogeneic hematopoietic stem cell transplantation for refractory or relapsed acute leukemia].
Sun J; Meng FY; Liu QF; Xu D; Xu B; Liu XL
Ai Zheng; 2003 Dec; 22(12):1321-4. PubMed ID: 14693060
[TBL] [Abstract][Full Text] [Related]
13. How can we improve life expectancy and quality of life in long-term survivors after allogeneic stem cell transplantation?
Savani BN
Semin Hematol; 2012 Jan; 49(1):1-3. PubMed ID: 22221778
[No Abstract] [Full Text] [Related]
14. Histological evaluation of acute mucocutaneous graft-versus-host disease in nonmyeloablative hematologic stem cell transplants with an observation predicting an increased risk of progression to chronic graft-versus-host disease.
Bridge AT; Nelson RP; Schwartz JE; Mirowski GW; Billings SD
Am J Dermatopathol; 2007 Feb; 29(1):1-6. PubMed ID: 17284954
[TBL] [Abstract][Full Text] [Related]
15. Time to explore preventive and novel therapies for bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation.
Sengsayadeth SM; Srivastava S; Jagasia M; Savani BN
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1479-87. PubMed ID: 22449611
[TBL] [Abstract][Full Text] [Related]
16. The impact of HLA-E polymorphisms in graft-versus-host disease following HLA-E matched allogeneic hematopoietic stem cell transplantation.
Hosseini E; Schwarer AP; Ghasemzadeh M
Iran J Allergy Asthma Immunol; 2012 Mar; 11(1):15-21. PubMed ID: 22427472
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic stem cell transplantation as treatment for heavily treated, refractory acute graft-versus-host disease after HLA-mismatched stem cell transplantation.
Ikegame K; Yoshihara S; Taniguchi Y; Kaida K; Inoue T; Okada M; Taniguchi K; Hasei H; Tamaki H; Fujioka T; Kato R; Soma T; Ogawa H
Exp Hematol; 2011 Aug; 39(8):880-90. PubMed ID: 21689724
[TBL] [Abstract][Full Text] [Related]
18. Emerging drugs for acute graft-versus-host disease.
Khaled Y; Reddy P; Krijanovski O
Expert Opin Emerg Drugs; 2009 Jun; 14(2):219-32. PubMed ID: 19519285
[TBL] [Abstract][Full Text] [Related]
19. Liver transplantation in a child with liver failure due to chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation from the same unrelated living donor.
Englert C; Ganschow R
Pediatr Transplant; 2012 Nov; 16(7):E325-7. PubMed ID: 22462486
[TBL] [Abstract][Full Text] [Related]
20. Sclerodermatous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: incidence, predictors and outcome.
Skert C; Patriarca F; Sperotto A; Cerno M; Filì C; Zaja F; Stocchi R; Geromin A; Damiani D; Fanin R
Haematologica; 2006 Feb; 91(2):258-61. PubMed ID: 16461315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
